Orchid Pharma Limited — Board Meeting, 11-11-2025: Outcome of Board Meeting

Orchid Pharma's Board greenlit Q2/H1 results. Consolidated Q2 saw a net loss of ₹5.72 Cr, but H1 delivered a net profit of ₹9.34 Cr. A major strategic play: Orchid acquired Allecra Therapeutics, gaining full global ownership of the antibiotic Enmetazobactam. Merger with Holding Company also progressing.